Antioxidant, biofilm inhibition and mutagenic activities of newly substituted fibrates

Asma Sheikh¹*, Zia-Ur-Rehman², Muhammad Imran¹, Zaid Mahmood¹

¹Institute of Chemistry, University of the Punjab, Lahore, ²Applied Chemistry Research Centre, PCSIR, Labs, Complex, Lahore, Pakistan

*For correspondence: Email: asmasheikhso@yahoo.com

Sent for review: 19 January 2019 Revised accepted: 25 May 2019

Abstract

Purpose: A series of benzylidene-2-(4-bromophenoxy)-2-methyl propane hydrazides (1-10) were synthesized and assay them for their biofilm inhibition, antioxidant and mutagenic.

Methods: All derivatives were prepared by condensation of various substituted benzaldehyde and acetonophenones with 2-(4-bromorophenoxy)-2-methyl propane hydrazide, which was itself prepared by hydrazinolysis of ethyl-2-(4-bromorophenoxy)-2-methyl propanoate and were characterized by FTIR, ¹H NMR, ¹³C NMR, mass spectrometry. They were screened for their in-vitro anti-oxidant, biofilm inhibition and mutagenicity by established methods.

Results: Anti-oxidant results revealed that the electron donating group enhanced the scavenging ability of the compounds as seen in compounds 4b, 4h and 4i. In biofilm inhibition studies, all compounds were more active against Gram –ive bacterial strain when compared to gram +ive strain. The mutagenicity assay results indicate that the compound having chloro group substitution is mutagenic.

Conclusion: The benzylidene compounds of 2-(4-bromophenoxy)-2-methyl hydrazide possessing electron donating substituents exhibit superior activities to the electron withdrawing group substituents.

Keywords: Fibrate derivatives, Anti-oxidant, Biofilm inhibition, Mutagenic activity

INTRODUCTION

Fibrates are a class of drugs having a stable phenoxy isobutyric acid (pharmacophore moiety) [1] used for the treatment of coronary heart disease, ischemic cerebrovascular diseases and peripheral vascular disorder [2]. Furthermore, these fibrates inhibit the accumulation of lipids in arteries and stimulate the production of high density lipoprotein cholesterol [3]. Guido Bargellini introduced the synthesis of fibric acid compound [4] and found it very responding to human bio-chemical system for the treatment of dyslipidemia. Later, many other fibrates like Bezaflibrate, Clofibrate, Fenofibrate and Ciprofibrate [5] were reported. In the last decade, scientists have coupled this moiety with various heterocyclic nuclei such as benzoxazole [6], indole-fibrate [7], amide-fibrate [8], tetrazole [9] and oxadizole [10] to get more potent biologically active compound.

Keeping in view the stable structure of fibrates, their tremendous biological activities and...
absence of disproportionation, the ethyl 2-(4-
 bromophenoxy)-2-methyl propanoate having
fibrate moiety was synthesized and converted
into biologically active azomethine compounds
and investigated their antioxidant, biofilm
inhibition and mutagenic properties with respect
to the presence substituents and azomethine
linkage.

EXPERIMENTAL

Chemicals, reagents and equipment

All the chemicals were purchased from E. Merck,
Sigma Aldrich and Fluka and were used without
purification. Bruker Tensor 27 spectrophotometer
used for IR spectra (in KBr disk). For 1H NMR
Bruker Avance-III instrument was used. TMS (tri-
methyl silane) was used as an internal standard
and chemical shifts were reported in ppm. For
 elemental analysis Perkin Elmer 2400-CHNS
Analyzer was used, while Melting points were
recorded on a Stuart scientific SMP3 apparatus and
are uncorrected.

General procedure for the synthesis of N´-
Benzylidene-2-(4-bromophenoxy)-2-methyl
propane hydrazides (5a-5j)

For the synthesis of azomethine derivatives,
using a modified literature method 2-(4-
Bromophenoxy)-2-methyl propanoic acid (1)
and ethyl-2-(4-bromophenoxy)-2-methyl
propanoate (2) were synthesized [11]. Ethyl-2-(4-
bromophenoxy)-2-methyl propanoate (2) was
converted into 2-(4-bromophenoxy)-2-methyl
hydrazide (3) by refluxing ethyl-2-(4-
bromophenoxy)-2-methyl propanoate (2) (0.01
mol) with hydrazine hydrate (0.01 mol) in the
presence of ethanol (30mL) for a period of 8hrs.
Completion of reaction was monitored by TLC
(hexane: ethyl acetate). The contents of flask
were reduced to half through distillation and
cooled to room temperature. The remaining
reaction mixture on constant stirring was acidified
with HCl (5%) to get the product which was
filtered, washed, dried and the yield of the
product obtained was 80%. Aromatic aldehydes
or acetonophenones (0.875 mmole), ethanol (30
mL) and phosphoric acid (1-2 drops) with 2-(4-
bromophenoxy)-2-methyl hydrazide (3) (200 mg;
0.875 mmole) were refluxed in round bottom
 flask for the period of 3-4 hrs. When the reaction
was completed (monitored by TLC), the content
of flask was cooled to room temperature and
evaporation of the solvent under vacuum yields
the solid product. The residue was purified by
recrystallization from ethyl alcohol.

Biofilm inhibition assay

The inhibition of biofilm formation was
determined following a reported procedure [12].
The wells of a sterile 96-well flat bottomed tissue
culture plates were filled with nutrient broth (100
µL, Oxoid, UK), testing sample (100 µL) and
bacterial suspension (20 µL) was inoculated.
Negative control wells contained nutrient broth
and microbial strain while positive control
contained standard antibiotic Rifampicin and
nutrient broth only. Tissue cultured Plates were
incubated under aerobic condition for 24 h at
37°C. Thereafter, each plate were treated with
buffer of pH: 7.2 (phosphate buffer) for removal
of non-adherent bacteria, for remaining bacteria
all plates were treated with methanol. Afterward
Crystal violet (50%) was used for staining and
excess stain rinsed off. The OD of each well was
measured at 630 nm using micro plate reader
(BioTek, USA) and bacterial growth inhibition
(INH) percent was calculated as in Eq 1.

\[
\text{INH} \% = \left(1 - \frac{OD_{\text{sample}}}{OD_{\text{control}}} \times 100\right)
\]

where \(OD\) = optical density.

Antioxidant assay

The antioxidant activity of compounds was
determined using 2, 2-diphenyl-1-picrylhydrazyl
(DPPH) spectrophotometric method [13] with
slight modification. 0.004 % (1 mL) of DPPH in
methanol was added to sample solution (3 mL)
and the mixture was kept in the dark for 30 min.
The decrease in absorbance was noted at 517
nm. Ascorbic acid was taken as the standard,
and inhibition (%) was calculated as in Eq 2.

\[
D \% = \left(\frac{A_0 - A_1 \times 100}{A_0}\right) \times 100
\]

where \(A_1\) = absorbance of sample; \(A_0\) =
absorbance of blank.

Mutagenic screening assay

Mutagenicity of synthesized compounds was
determined by Ames bacterial reverse-mutation
method [14]. A fresh strain of Salmonella culture
(test strain), sample solution, standard and
reagent mixture were combined in the following
ratio (Table 1).

Mutant strains of Salmonella (TA98 and TA100)
were used. The prepared contents (200 µL) was
dispensed into each well of a 96-well micro
titration plate and incubated at 37 °C for 4 days.
The blank plate was first observed and the rest of plates were read only when all wells in the blank plate were colored purple—an indication that the assay was not contaminated. The background, standard, and test plates observed visually, all yellow, partial yellow or turbid wells were scored as positive wells while purple wells were scored as negative. For a compound to be mutagenic, the number of positive wells had to be more than twice the number of positive well in the background plate.

RESULTS

Chemistry

2-(4-Bromophenoxy)-2-methyl propane hydrazide (3), was synthesized by hydrazinolysis of ethyl 2-(4-bromophenoxy)-2-methyl propanoate (2) which was obtained by the esterification of 2-(4-bromophenoxy)-2-methyl propanoic acid (1) in the presence of sulfuric acid as catalyst (Figure-1). Condensation of aromatic aldehydes and acetonophenones with 2-(4-bromophenoxy)-2-methyl propane hydrazide (3) in ethanol yields the benzylidene-2-(4-bromophenoxy)-2-methyl propane hydrazide (4a-4j) compounds, all the compounds were characterized by using different spectroscopic techniques (FTIR, \(^1\)H NMR, \(^{13}\)C NMR and mass spectrometry). Compounds (4a-4j) are white to pale yellow crystalline solids. They exhibit sharp melting points and are fairly soluble in ethanol and other common organic solvents.

The presence of functional groups in compounds (4a-4j) were established using FTIR spectroscopy by comparing their spectra with precursors. Useful information obtained are as follows; the appearance of characteristic peak of \(-\text{NH}\) around 3240 cm\(^{-1}\) indicate the conversion of primary amine into secondary amine which is related to reported value of 3120 - 3330 cm\(^{-1}\) [15]. The absence of peak at range of 1700 - 1750 cm\(^{-1}\) further confirmed the conversion of aldehyde (\(-\text{CHO}\)) and acetonophene (\(-\text{C}=\text{O}\)) group into \(-\text{C}=\text{N-}\) linkage [16]. Appearance of two other characteristic peaks between 1583 - 1600 cm\(^{-1}\) and 1715 - 1759 cm\(^{-1}\) can be attributed to \(-\text{C}=\text{N}\) and \(-\text{C}=\text{O}\) respectively and are closely related with the literature value of acetate and azomethine moiety (1590 - 1670 cm\(^{-1}\) and 1720 - 1750 cm\(^{-1}\)) [17]. The presence of these functional groups NH, \(-\text{C}=\text{N}\) and \(-\text{C}=\text{O}\) agree with the proposed structures of desired derivatives.

\(^1\)H NMR spectra were recorded in DMSO-d6 and the values of chemical shifts are given in the experimental section. The important peaks of -NH and methyl group \(-\text{C}(\text{CH}_3)\) protons appears at 9.68 - 11.11 ppm and 1.49-1.64 ppm respectively. A strong singlet peak of -\text{CH} of the aldehyde group in 4a, 4b, 4c, 4d, 4e and 4f appears between 8.12 - 8.72 ppm [18]. Similarly, azomethine compounds synthesized from acetonophenones (4g, 4h, 4i and 4j) also shows sharp singlet peak of -\text{CH} around 2.20 - 3.85 ppm which are close to literature value of 2.50 ppm [19]. The azomethine ligands shows multiplet signals around 6.88 - 7.99 ppm which can be assigned as protons of benzene ring. The presence of substituents on benzene ring greatly affects the chemical shift values as seen in 4h whereas the hydroxyl group present at the ortho position appears as a singlet at 9.64 ppm which is close to the literature value of 10.22 ppm [20]. In \(^{13}\)C-NMR, the representative amide group peak in all compounds appears in the range of 168-155 ppm which matches reported value of 167 - 152 ppm. Similarly, aromatic carbon atoms were seen between 110-150 ppm depending on their electronic environment and non-aromatic carbon atoms found in the methoxy group of 4b and 4i were observed at 55.32ppm which correlates with reported value of 55.91ppm [21]. The methyl group in 4g, 4h, 4i and 4j shows a sharp signal at 25.29 ppm.

![Figure 1: Synthesis of benzylidene-2-(4-bromophenoxy)-2-methyl propane hydrazide](image-url)

| Variable          | Standard | Sample | Volume used (mL) | Reagent mixture | Deionized water | Test strain |
|-------------------|----------|--------|------------------|-----------------|-----------------|-------------|
| Blank             | -        | -      | 2.5              | 17.5            | -               | -           |
| Background        | -        | -      | 2.5              | 17.5            | 0.005           | -           |
| Standard Mutagen  | 0.1      | -      | 2.5              | 17.4            | 0.005           | -           |
| (test) sample     | -        | 0.005  | 2.5              | 17.5            | 0.005           | -           |

| Test strain | Mutagenic | Non-mutagenic |
|-------------|-----------|---------------|
| 0.005       | 2.5       | 17.5          |
| 0.005       | 2.5       | 17.5          |
| 0.005       | 2.5       | 17.5          |

Table 1: Ratio of standards and compounds
4-Bromobenzyliodene-2-(4-chlorophenoxy)-2-methylpropanehydrazide (4a)

Light yellow crystals; Yield 72 %; m.p, 176-177°C; IR (KBr cm⁻¹): 3241(NH), 1745(C=O), 1625(C=N); ¹H NMR (DMSO-d₆, 300 MHz): 9.74 (s, 1H, NH), 8.12 (s, 1H, CH), 7.76-7.68 (m, 2H, ArH), 7.41-7.37 (m, 2H, ArH), 7.28 - 7.25 (m, 2H, ArH), 6.95 - 6.91 (m, 2H, ArH), 1.62 (s, 6H, C(CH₃)₃); ¹³C NMR (DMSO, 100 MHz): 168.52, 152.74, 145.86, 138.22, 132.50, 131.97, 129.58, 129.05, 128.73, 120.19, 82.33, 25.29; ESIMS m/z (%): 395.6[M+1]⁺; Anal. Calcd for: C₁₇H₁₉BrCINO₂; C, 58.13; H, 4.59; N, 7.98; Found C, 58.12; H, 4.56; N, 8.01.

2-(4-Bromobenzyliodene)-2-methyl-(3-nitrobenzyliodene) propanehydrazide (4e)

Pale yellow powder; Yield 87%; m.p: 175-177°C; IR (KBr cm⁻¹): 3041(NH), 1723(C=O), 1600(C=N); ¹H NMR (DMSO-d₆, 300 MHz): 10.11 (s, 1H, NH), 8.46 (td, J = 1.8, 1.1 Hz, 1H, CH), 8.12 - 8.01 (m, 1H, ArH), 8.01 - 7.90 (m, 2H, ArH), 7.78 (t, J = 7.8 Hz, 1H, ArH), 7.40 - 7.29 (m, 2H, ArH), 6.85-6.74 (m, 2H, ArH), 1.52 (s, 6H, C(CH₃)₃); ¹³C NMR (DMSO, 100 MHz): 168.52, 152.74, 147.43, 145.73, 138.88, 132.50, 132.58, 129.73, 123.65, 120.19, 82.33, 25.29; ESIMS m/z (%): 407.0[M+1]⁺; Anal. Calcd for: C₁₇H₁₉BrN₂O₂; C, 56.44; H, 4.46; N, 11.61; Found C, 56.52; H, 4.55; N, 11.54.

4-Bromobenzyliodene-2-(4-bromophenoxy)-2-methylpropanehydrazide (4f)

White crystal; Yield 69 %; m.p: 201-203°C; IR (KBr cm⁻¹): 3041(NH), 1721(C=O), 1583(C=N); ¹H NMR (DMSO-d₆, 300 MHz): 11.66 (s, 1H, NH), 8.37 (s, 1H, CH), 7.85 - 7.58 (m, 2H, ArH), 7.75 - 7.68 (m, 2H, ArH), 7.40 - 7.29 (m, 2H, ArH), 6.82 - 6.72 (m, 2H, ArH), 1.53 (s, 6H, C(CH₃)₃); ¹³C NMR (DMSO, 100 MHz): 168.52, 152.74, 145.86, 136.22, 132.50, 131.97, 129.58, 129.00, 128.73, 120.19, 82.23, 25.29; ESIMS m/z (%): 441.9[M+1]⁺; Anal. Calcd for: C₁₇H₁₉BrN₂O₂; C, 51.60; H, 4.09; N, 7.07; Found C, 51.68; H, 4.15; N, 6.87.

2-(4-Bromobenzyliodene)-(1-(4-chlorophenyl) ethyldiene)-2-methylpropanehydrazide (4g)

Off white powder; Yield 79 %; m.p: 212-213°C; IR (KBr cm⁻¹): 3214(NH), 1757(C=O), 1592(C=N); ¹H NMR (DMSO-d₆, 300 MHz): 10.01 (s, 1H, NH), 7.66 - 7.56 (m, 2H, ArH), 7.33 (ddt, J = 10.3, 8.9, 1.7 Hz, 4H, ArH), 7.00 - 6.91 (m, 2H, ArH), 2.27 (s, 3H, CH₃), 1.51 (s, 6H, C(CH₃)₃); ¹³C NMR (DMSO, 100 MHz): 168.52, 152.74, 145.04, 143.75, 143.26, 132.50, 132.58, 129.40, 129.73, 120.19, 82.23, 25.29; ESIMS m/z (%): 410.1[M+1]⁺; Anal. Calcd for: C₁₈H₁₈BrCINO₂; C, 59.18; H, 4.97; N, 7.67; Found C, 59.22; H, 4.02; N, 7.66.

2-(4-Bromobenzyliodene)-(1-(2-hydroxyphenyl) ethyldiene)-2-methylpropanehydrazide (4h)

White powder; Yield 77%; m.p: 188-190°C; IR (KBr cm⁻¹): 3233(NH), 1759(C=O), 1598(C=N); ¹H NMR (DMSO-d₆, 300 MHz): 12.63 (s, 1H, NH), 9.64 (s, 1H, OH), 7.47-7.44 (dd, J = 7.7, 6.9 Hz, 6H, C(CH₃)₃).
2-(4-Bromophenoxy)-(1-(4-methoxyphenyl) ethylidene)-2-methylpropanehydrazide (4i)

Pale yellow powder; Yield: 62%; m.p:191-192°C; IR (KBr) cm⁻¹: 3224(NH), 1715(C=O), 1596(C=N); ¹H NMR (DMSO. d₆ 300 MHz): 9.56 (s, 1H, NH), 7.85 – 7.81 (m, 2H, ArH), 7.31 – 7.26 (m, 2H, ArH), 6.98 – 6.90 (m, 4H, ArH), 3.85 (s, 3H, CH₃), 3.20 (s, 3H, OCH₃). ¹³C NMR (DMSO, 100 MHz): 169.1, 161.36, 152.74, 148.77, 132.50, 129.58, 129.47, 128.98, 120.19, 112.93, 82.42, 55.32, 25.29, 13.89; ESI-MS m/z (%): 406.1[M+H]+; Anal. Calcd for: C₁₂H₁₂BrN₂O₂: C, 62.33; H, 5.52; N, 8.07; Found C, 62.25; H, 5.44; N, 8.19.

2-(4-Bromophenoxy)-2-methyl-1-(phenylethylidene) propane hydrazide (4j)

White crystalline powder; Yield: 81%; m.p:202-204°C; IR (KBr) cm⁻¹: 3321(NH), 1759(C=O), 1591(C=N); ¹H NMR (DMSO. d₆ 300 MHz): 9.63 (s, 1H, NH), 7.87-7.83 (m, 2H, ArH), 7.42 – 7.39 (m, 3H, ArH), 7.31-7.26(m, 2H, ArH) 6.98 – 6.93 (m, 2H, ArH), 2.23 (s, 3H, CH₃), 1.62 (s, 6H, C(CH₃)₂). ¹³C NMR (DMSO, 100 MHz): 169.14, 152.74, 148.92, 136.63, 132.50, 129.90, 129.58, 127.51, 127.28, 120.19, 82.42, 25.29, 13.89; ESI-MS m/z: 375.1[M+H]+; Anal. Calcd for: C₁₈H₁₉BrN₂O₂: C, 63.24; H, 5.89; N, 7.76; Found C, 63.12; H, 5.75; N, 7.88.

All the synthesized compounds were subjected to biofilm inhibition, antioxidant and mutagenic assay using well-defined literature methods.

Biofilm inhibition activity

A microtitre-plate method was used to determine the inhibitory activity of compounds in biofilm formation. All the compounds showed sensitivity against gram-positive and gram-negative strains of bacteria. Rifampicin (Oxoid, UK) were used as standard antibiotic (positive control) to compare sensitivity of azomethin compounds in biofilm inhibition. It was found that the inhibition assay depends upon the ability of azomethine compounds to form a chelate with bacterial strains and inhibit their growth [22]. Table 2 shows that all compounds are more active against E. coli gram-negative bacterial strain than the gram-positive bacterial strain.

| Compound | Biofilm inhibition \% (S.aureus) | Biofilm inhibition \% (E.coli) |
|----------|---------------------------------|-----------------------------|
| 4a       | 57.84                           | 75.33                       |
| 4b       | 77.28                           | 79.22                       |
| 4c       | 57.39                           | 75.92                       |
| 4d       | 57.29                           | 49.46                       |
| 4e       | 55.65                           | 74.14                       |
| 4f       | 43.18                           | 75.63                       |
| 4g       | 63.31                           | 57.07                       |
| 4h       | 57.01                           | 60.41                       |
| 4i       | 75.51                           | 77.05                       |
| 4j       | 61.26                           | 65.22                       |

Positive control: Rifampicin (Rifimpacin)

Anti-oxidant activity

The anti-oxidant activity was evaluated by the radical scavenging ability of compounds by using 1, 1-diphenyl-2-picrylhydrazyl (DPPH). In this series, the scavenging potential lies between moderate to good yield as shown in Table 3 when compare with the scavenging potential of standard compound. In Compound 4b and 4i the presence of methoxy group at the ortho and para position of the aromatic ring enhance the scavenging ability.

| Compound | DPPH (%) |
|----------|----------|
| 4a       | 51.22    |
| 4b       | 89.45    |
| 4c       | 23.96    |
| 4d       | 56.56    |
| 4e       | 55.28    |
| 4f       | 62.80    |
| 4g       | 51.00    |
| 4h       | 71.77    |
| 4i       | 82.54    |
| 4j       | 67.12    |

Ascorbic acid: 92.47

Mutagenic activity

Mutagenic screening of compounds was evaluated by Ames bacterial reverse-mutation method. All the compounds were sensitive against both strains of salmonella TA98 and TA100. The result (Table 4) shows that most of the compounds were non-mutagenic or mutagenic for only one strain under assay condition.
Table 4: Mutagenic screening of benzylidene-2-(4-bromophenoxy)-2-methyl propane hydrazide

| Variable       | TA 98 | TA 100 |
|----------------|-------|--------|
|                | No. of +ve wells/total no. of wells | Result | No. of +ve wells/total no. of wells | Result |
| Standard Background | 84/96 | Mutagenic | 79/96 | Mutagenic |
| 4a | 11/96 | Non-mutagenic | 10/96 | Non-mutagenic |
| 4b | 10/96 | Non-mutagenic | 10/96 | Mutagenic |
| 4c | 9/96 | Non-mutagenic | 10/96 | Non-mutagenic |
| 4d | 10/96 | Non-mutagenic | 16/96 | Non-mutagenic |
| 4e | 22/96 | Mutagenic | 24/96 | Mutagenic |
| 4f | 22/96 | Mutagenic | 10/96 | Non-mutagenic |
| 4g | 8/96 | Non-mutagenic | 8/96 | Non-mutagenic |
| 4h | 5/96 | Non-mutagenic | 20/96 | Mutagenic |
| 4i | 10/96 | Non-mutagenic | 9/96 | Non-mutagenic |
| 4j | 11/96 | Non-mutagenic | 10/96 | Non-mutagenic |

The compound 4d only shows greater interaction for DNA to make it stable and causes genetic mutation [23].

DISCUSSION

It was found that organic ligands having azomethine linkage were synthesized by the condensation reaction of amines (primary or secondary) with benzaldehyde/acetophenones. They are diverse class of compounds which have broad range of biological activities such as antibacterial, antifungal, enzyme inhibition, antitumor and antipyretic activities [24]. All the compounds were characterized by spectroscopic techniques. For functional group confirmation, in FTIR spectra the characteristic peak of –NH around 3240 cm\(^{-1}\) and azomethine appears at range of 1530 - 1600 cm\(^{-1}\) confirmed the synthesis of product, similarly in \(^1\)H NMR the peak of NH\(_2\) around 4.50 - 5.20 ppm was absent, the two prominent singlet peaks of –CH at range of 8.12 - 8.72 ppm and six protons of – (CH\(_3\)\(_2\)) support the presence of fibrate moiety and azomethine linkage in benzylidene compound.

The results of biofilm inhibition revealed that all the ligands were active against gram-negative bacterial strain as compare to gram-positive strain. Literature shows that bacterial cell wall is composed of peptidoglycan which is thicker in Gram-positive strains and thinner in Gram-negative strains [25] due to which ligands can easily penetrate through the cell wall of gram-negative bacteria as compare to gram-positive bacteria and disturb cell growth to biofilm formation. Similarly ligands face a barrier for diffusion in Gram positive strain of bacteria [26] and was responsible for the low activity shown by some of the compounds. The compound 4b and 4i behave more potent as compare to all other compounds, it may be due to the presence of oxidative methoxy group whose strong oxidative nature crucially attacked the cell wall of microbes and damaged its growth. [27]

The azomethine compounds have an efficient conjugated system of delocalized electrons and form a stable radicals [28] which makes them an excellent antioxidant. The results in Table 3 shows that the compounds substituted with electron donating group as in 4b and 4i have more scavenging activity, while the presence of electron withdrawing substituents (Cl, Br) have the least effect on delocalization and hence, they shows poor activity.

In mutagenic screening result, it was found that most of the compounds shows different mutagenicity behavior against both strains of Salmonella TA98 and TA 100.

Literature shows that the position and nature of substituents on phenyl ring greatly effect the mutagenic results [29] as in compound 4d chloro group is present at Meta position of phenyl ring and causes mutagenicity against both strains of Salmonella TA98 and TA 100 while in compound 4e nitro group is also present at meta position but it is mutagenic only for one strain. It shows that chloro and nitro groups at meta position creates greater interaction with DNA and becomes stable [30] and this stability causes genetic mutation in bacterial strains.

CONCLUSION

Azomethine derivatives of benzylidene-2-(4-bromophenoxy)-2-methyl propane hydrazide have been successfully synthesized by following well-defined procedures and their structures confirmed by IR, NMR and mass spectrometry.
These compounds exhibit significant biological activities which are linked to the position and type of substituents on the structure of azomethine compounds. These findings may be helpful in the synthesis of more potent bioactive azomethine compounds.

DECLARATIONS

Acknowledgement

The authors acknowledge Higher Education Commission of Pakistan for financial grant to Quaid Azam University Islamabad for spectral analysis and University of Agriculture Faisalabad for providing facilities in biological screening.

Conflict of interest

No conflict of interest is associated with this work.

Contribution of authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/reamd), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

1. Li JJ. Bargellini reaction. Name Reactions: A Collection of Detailed Reaction Mechanisms. Springer, Berlin, Heidelberg 2006; pp 24-25.
2. Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, Araki T, Oda S, Inoue K, Shibuya K, Staels B. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists. Bioorg Chem Lett 2007; 17(16): 4689-4693.
3. Desai RC, Metzger E, Santini C, Meinke PT, Heck JV, Berger JP, MacNaul KL, Cai TQ, Wright SD, Agrawal A, Moller DE. Design and synthesis of potent and subtype-selective PPARα agonists. Bioorg Chem Lett 2006; 16(6): 1673-1678.
4. Cvetovich RJ, Chung JY, Kress MH, Amato JS, Matty L, Weingarten MD, Tsay FR, Li Z, Zhou G. An efficient synthesis of a dual PPAR α/γ agonist and the formation of a sterically congested α-arylxyisobutyric acid via a Bargellini reaction. J Org Chem 2005; 70(21):8560-8563.
5. Dolaz M, McKee V, Golcu A, Tumer M. Synthesis, Structural Characterization, Spectroscopic and Electrochemical Studies of N, N′-bis [2-(4-dimethoxyphenyl) methylidene] butane-1, 4-diamine. Curr Org Chem 2010; 14(3): 281-288.
6. Pingali H, Jain M, Shah S, Makadia P, Zaware P, Goel A, Patel M, Giri S, Patel H, Patel P. Design and synthesis of novel oxazole containing 1, 3-Dioxane-2-carboxylic acid derivatives as PPAR α/γ dual agonists. Bioorg Med Chem 2008; 16(15): 7117-7127.
7. Liu W, Liu K, Wood HB, McMann AG, Doebber TW, Chang CH, Akiyama TE, Einstein M, Berger JP, Meinke PT. Discovery of a peroxisome proliferator activated receptor γ (PPARγ) modulator with balanced PPARα activity for the treatment of type 2 diabetes and dyslipidemia. J Med Chem 2009; 52(14): 4443-4453.
8. Sashidhara KV, Palnati GR, Dodda RP, Sonkar R, Khanna AK, Bhatia G. Discovery of amide based fibrates as possible antidiyslipidemic and antioxidant agents. Eur J Med Chem 2012; 57: 302-310.
9. Navarrete-Vázquez G, Alainz-Palacios A, Hidalgo-Figueroa S, González-Acevedo C, Ávila-Villarreal G, Estrada-Soto S, Webster SP, Medina-Franco JL, López-Vallejo F, Guerrero-Alvarez J, Tlahuex H. Discovery, synthesis and in combo studies of a tetrazole analogue of clofibric acid as a potent hypoglycemic agent. Bioorg Med Chem Lett 2013; 23(11): 3244-3247.
10. Akhter M, Husain A, Azad B, Ajmal M. Aroylpropionic acid based 2, 5-disubstituted-1, 3-oxadiazoles: Synthesis and their anti-inflammatory and analgesic activities. Eur J Med Chem 2009; 44(6): 2372-2378.
11. Rehman MZ, Kazi AA, Siddiqui HL, Kashmari MA, Ahmad VU. An efficient method for the synthesis of alky 2-(4-benzoylphenoxy)-2-methyl propanoates. J Chem Soc Pak 2007; 29(4): 352-356.
12. Shahid S A, Anwar F, Shahid M, Majeed N, Azam A, Bashir M,Shakir I. Laser-Assisted synthesis of Mn 0.50 Zn 0.50 Fe 2 O 4 nanomaterial: characterization and in vitro inhibition activity towards bacillus subtilis biofilm. J Nanomater 2015; 16(1): 111-116.
13. Beilik Y. Total antioxidant activity and antimicrobial potency of the essential oil and oleoresin of Zingiber officinalis Roscoe. Asian Pac J Trop Dis 2014; 4(1): 40-44.
14. Tejs S. The Ames test: a methodological short review. Environ Biotech 2008; 4: 7-14.
15. Bharti SK, Nath G, Tilak R, Singh SK. Synthesis, antibacterial and anti-fungal activities of some novel Schiff bases containing 2, 4-disubstituted thiazole ring. Eur J Med Chem 2010; 45(2): 651-660.
16. Alaghaz AN, Bayoumi HA, Ammar YA, Aldhimani SA. Synthesis, characterization, and antipathogenic studies of azomethine compounds. Trop J Pharm Res, June 2019; 18(6): 1233.
of some transition metal complexes with N, O-chelating Schiff's base ligand incorporating azo and sulfonamide Moieties. J Mol Stru 2013; 1035: 383-399.

17. Shanty AA, Philip JE, Sneha EJ, Kurup MR, Balachandran S, Mohanan PV. Synthesis, characterization and biological studies of Schiff bases derived from heterocyclic moiety. Bioorg chem 2017; 70: 67-73.

18. Shelke VA, Jadhav SM, Patharkar VR, Shankarwar SG, Munde AS, Chondhekar TK. Synthesis, spectroscopic characterization and thermal studies of some rare earth metal complexes of unsymmetrical tetradentate Schiff base ligand. Arabian J Chem 2012; 5(4): 501-507.

19. Kotkar SN, Juneja HD. Synthesis, Characterization, and Antimicrobial Studies of N, O Donor Schiff Base Polymeric Complexes. J Chem 2013; 2013:

20. Chohan ZH, Sumra SH, Youssoufi MH, Hadda TB. Metal based biologically active compounds: Design, synthesis, and antibacterial/antifungal/cytotoxic properties of triazole-derived Schiff bases and their oxovanadium (IV) complexes. Eur J Med Chem 2010; 45(7): 2739-2747.

21. Trávníček Z, Buchlík R, Nemec I. Novel Schiff Bases Based on the Quinolinone Skeleton: Syntheses, X-ray Structures and Fluorescent Properties. Molecules 2014; 19(9):13509-13525.

22. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipid 2002; 13(4): 415-420.

23. Özkay Y, Incesu Z, Işıkdağ I, Yeşilkaya M. Antiproliferative effects of some N-benzylideneanilines. Cell Biochem. Funct. 2008; 26(1): 102-106.

24. Tobriya, S K. Biological Applications of Schiff base and its Metal Complexes-A Review. Int J Sci Res 2014; 3(9): 1254-1256.

25. Sangshetti JN, Khan FA, Patil RH, Marathe SD, Gade WN, Shinde DB. Biofilm inhibition of linezolid-like Schiff bases: synthesis, biological activity, molecular docking and in silico ADME prediction. Bioorg Med Chem Lett 2015; 25(4): 874-880.

26. Ejiah FN, Fasina TM, Familioni OB, Ogunsola FT. Substituent effect on spectral and antimicrobial activity of Schiff bases derived from amino benzoic acids. Adv Bio Chem 2013; 3(05): 475-479.

27. Nel AE, Mâdlar L, Velegol D, Xia T, Hoek EM, Somasundaran P, Klaessig F, Gastranova V, Thompson M. Understanding biophysicochemical interactions at the nano–bio interface. Nat Mater 2009; 8(7): 543-557.

28. Iftikhar B, Javed K, Khan MS, Akhter Z, Mirza B, Mckee V. Synthesis, characterization and biological assay of Salicyaldehyde Schiff base Cu (II) complexes and their precursors. J Mol Struct 2018; 1155: 337-348.

29. Aydoğan, G, Kutlu, M. Mutagenic activities of ten imidazole derivatives in Salmonella typhimurium. Biologia 2007; 62(1): 6-12.

30. Alanyali FS, Artagan Ö, Yuksel S. Mutagenicity Studies of some Substituted Benzylideneaniline Derivatives. Int J Pharm 2011; 7(2): 278-282.